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we not then say that all who were part of that generation were
part of the First?
Frank H. Leeds, MD
Clinical Professor Emeritus
University of California
San Francisco, Calif
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Competition of interest: FHL was associated with Dr Norman E. Freeman
in research, teaching, and private practice of vascular surgery from July
1946 to September 1957.
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Regarding “Preprocedural risk stratification:
Identifying an appropriate population for carotid
stenting”
We read with interest the article by Dr Ouriel and his col-
leagues from The Cleveland Clinic Foundation (J Vasc Surg
2001;33:728-32). There is a recent nationwide explosion of
interest in treating patients at high risk for carotid endarterec-
tomy (CEA) with percutaneous angioplasty and stenting (CAS).
Similar to the conclusion arrived at by Ouriel et al, we randomly
assigned patients with significant baseline comorbid conditions
(cardiac, recurrent stenosis, radiation stenosis, and contralateral
occlusion) to CEA or CAS.
Significant numbers in both treatment groups had grade 3
(SVS/AAVS) cardiac (CAS 72%, CEA 60%; P = .44) and hyper-
tensive (CAS 82%, CEA 80%; P = .65) risk factors. Contralateral
carotid disease (>50% stenosis, occlusion, or prior endarterec-
tomy) was present in 64% of the CAS group and in 60% of the
CEA group. Significantly more reversible cardiac events (hypoten-
sion/bradycardia requiring ≥24 hours of pharmacological sup-
port) were observed in the CAS group (CAS 73%, CEA 20%; P =
.03). Major adverse in-hospital events were noted in one patient in
each group (CAS, myocardial infarction; CEA, death). Local com-
plications were observed in one from each treatment group (CAS
groin hematoma; CEA, recurrent laryngeal nerve paralysis). The
duration of postoperative stay did not reach statistical significance
(CAS, 2.1 ± 1.4 days; CEA, 1.8 ± 1.1 days). However, four
patients in the CAS treatment group were readmitted within 1
month (congestive heart failure, 1; myocardial infarction, 1; rest
pain, 1), compared with no new events in the CEA group.
A disturbing number of patients in the CAS treatment group
experienced profound and prolonged hypotension and bradycar-
dia induced by forced dilatation of the carotid sinus. These phys-
iological changes were not well tolerated by patients with
underlying cardiac risk factors. Based on the findings of our study
population, a treatment algorithm is currently used before ran-
domization (Fig 1). Routine cardiac stress evaluation and coro-
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nary revascularization if possible significantly reduced the adverse
cardiac events noted following CAS. Patients with uncorrectable
cardiac disease are currently not offered CAS at our institution.
Our findings are similar to a study by Gil-Peralta et al1 who
also reported a high incidence of cardiovascular effects: hypoten-
sion (54.1%), bradycardia (67.1%), and asystole in 25.9% of
treated patients. Accurate stent sizing using an intravascular ultra-
sound to measure the normal caliber of the distal internal carotid
artery (ICA), combined with isolated ICA stent placement 
(Fig 2) has also decreased the incidence of post-CAS bradycardia
and hypotension. Evolving technology, such as the development
Fig 1. Treatment algorithm used before randomization.
Fig 2. Isolated stenting of the ICA.
of tapered stents to accommodate for the size mismatch between
the ICA and the common carotid artery, may exert less expansile
force on the carotid sinus.
In conclusion, patients with “significant baseline comorbid
conditions” may be placed at a greater risk with CAS. It is cur-
rently unclear if CAS can compete successfully with CEA in a
lower risk group. We are grateful to Ouriel et al for supplying us
with this very interesting information.
Karthikeshwar Kasirajan, MD
University of New Mexico
Albuquerque, NM
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Reply
The points raised by Dr Kasirajan and colleagues are quite
interesting and corroborate our own anecdotal findings. We, like
they, have noted quite disturbing drops in heart rate and blood
pressure during balloon dilatation at the carotid bulb. Interestingly,
these changes do not appear to be as profound in patients with
recurrent stenosis, presumably because the carotid sinus nerve has
been disturbed at the time of carotid endarterectomy.
As Dr Kasirajan suggests, these hemodynamic changes are
poorly tolerated by the very category of patients for whom
carotid stenting might be appropriate: those patients with
severe medical comorbidities. It is hopeful that the large ran-
domized studies will help to sort out just the problems that
have been identified by the Albuquerque group. Multivariate
analyses of important clinical endpoints should shed light on
exactly which patients are best served by carotid stenting or
carotid endarterectomy.
Kenneth Ouriel, MD, FACS, FACC
Department of Vascular Surgery
The Cleveland Clinic Foundation
Pepper Pike, Ohio
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Regarding “High prevalence of mild
hyperhomocysteinemia in patients with abdominal
aortic aneurysm”
We read with interest the paper by Brunelli et al (J Vasc Surg
2000;32:531-6), as it exactly mirrors our own results published in
abstract form. We have also studied homocysteine in patients with
abdominal aortic aneurysm (AAA) coming to surgery and reported
similar preliminary results in 14 AAA patients with 71% having
homocysteine levels above the 95th percentile and mean homocys-
teine levels higher than in a comparable control group (17.8 vs 11.8
µmol/L; P = .027, Mann-Whitney).1 Since that report we have
recruited a further 46 patients for a total of 60 patients and recently
reported homocysteine levels above the 95th percentile in 48% of
the AAA patients (mean levels, 13.1 vs 10.9 µmol/L; P = .003,
Mann-Whitney).2 One interesting omission from the Brunelli paper
was information on folate status and creatinine levels. These are
both strong predictors of homocysteine levels,3,4 and a significant
proportion of AAA patients will have some degree of renal impair-
ment. Even mild renal impairment can lead to impaired clearance of
homocysteine and raised plasma homocysteine levels. Did the
authors examine folate and creatinine status in their aneurysm
patients, and if so, did these variables influence their results?
Stuart Caldwell, FRCS
Timothy Sykes, FRCS
Damien Mosquera, MD, FRCS
Department of Vascular Surgery
Birmingham Heartlands Hospital
Birmingham, West Midlands, United Kingdom
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